Drugmaker Valeant raises profit forecast; shares spike
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
RBC Capital Comments on Valeant (VRX) Earnings
May 9, 2017 10:29 AM EDTRBC Capital maintains Sector Perform Valeant Pharmaceuticals (NYSE: VRX).
Analyst Douglas Miehm comments to clients that his team requires more details relating to Branded Rx revenues even though most investors seem to "find comfort in the Adj. EBITDA guidance increase." He closes... More



